How to avoid losing funding during the course of a clinical trial?
Securing public funding for a clinical trial or research project is a significant achievement for the scientific team and sponsor. However, the allocation of funds is just the beginning of a responsible and demanding project implementation phase. Funding institutions—whether national agencies, European programs, or sector-specific funds—expect strict adherence to the timeline, budget, and scientific assumptions outlined in the proposal. Failing to meet these obligations can lead to the suspension of funding, financial corrections, or, in extreme cases, the need to return part of the funds.
One of the most common reasons for the risk of losing funding is project delays, especially during the start-up phase of the trial. Issues such as obtaining regulatory approvals, prolonged negotiations with research sites, or underestimating the time needed for document preparation can cause delays in relation to the grant timeline. Funding institutions allow for changes in deadlines, but they require appropriate justification and formal notification. Failure to respond to delays is one of the most common causes of problems during project audits.
Another key risk area is the misallocation of funds in comparison to the approved budget. Publicly funded projects are subject to strict cost eligibility rules, and even operationally justified changes may require prior approval from the funding institution. In practice, difficulties arise when expanding the scope of services, changing the number of research sites, or requiring additional statistical analyses. Therefore, it is crucial to continuously monitor the budget and identify situations that may require amending the contract early on.
A further factor increasing the risk of losing funding is incomplete documentation and incorrect progress reporting. Funding institutions require regular scientific and financial reports, which must align with the clinical trial documentation. Discrepancies between grant reports and the actual progress of the study may be considered non-compliance with the funding requirements. Proper document archiving, tracking changes, and maintaining a complete audit trail are of particular importance.
Regulatory and quality issues cannot be overlooked either. Non-compliance with ICH GCP standards, issues with monitoring research sites, or improper data management can result not only in regulatory consequences but also in the funding institution questioning the validity of the project’s implementation. In public projects, the operational quality of the study is directly linked to the financial security of the project.
In practice, the most effective way to reduce risk is active project management from the early months of the trial. This includes realistic timeline planning, regular progress analysis, ongoing budget control, and quick responses to deviations from the plan. More and more sponsors are utilizing CRO support in this area, which helps to combine the regulatory requirements of the clinical trial with the obligations arising from the grant agreement.
The Biostat team supports sponsors of publicly funded projects in managing the execution of trials, monitoring compliance with funding assumptions, and preparing the documentation required for reporting and audits. This approach not only ensures that the trial is conducted according to GCP standards but also secures the financial stability of the project at every stage of its implementation.
Proper management of a grant-funded project is not only about conducting research according to the scientific plan. It is primarily about the ability to foresee administrative and financial risks and respond to them before they become a real threat to funding. This is why well-planned operational support from the start of the trial often determines its successful and secure completion.
